Insight into pain-inducing and -related gene expression: A challenge for development of novel targeted therapeutic approaches

Fundamental and Clinical Pharmacology

Volumn 25, Issue 1, 2011, Pages 48-62

  Vasileiou, Ioanna ^a   Giaginis, Constantinos ^a   Klonaris, Chris ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Catechol O methyltransferase; Genomics; Melanocortin 1 receptor; Morphine; Opioid receptor; Pain signaling proteomics

Indexed keywords

CATECHOL METHYLTRANSFERASE; MELANOCORTIN 1 RECEPTOR; MORPHINE; MU OPIATE RECEPTOR;

GENE EXPRESSION; GENOMICS; NEUROPATHIC PAIN; NOCICEPTION; PAIN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

ANALGESICS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENE EXPRESSION REGULATION; GENOMICS; HUMANS; PAIN; PROTEOMICS;

EID: 78650950966     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00809.x     Document Type: Review

References (172)

1. Woolf C.J. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann. Intern. Med. (2004) 140 441-451.
2. Julius D., Basbaum A.I. Molecular mechanisms of nociception. Nature (2001) 413 203-210.
3. Woolf C.J., Salter M.W. Neuronal plasticity: increasing the gain in pain. Science (2000) 288 1765-1769.
4. Mogil J.S., Yu L., Basbaum A.I. Pain genes?: natural variation and transgenic mutants. Annu. Rev. Neurosci. (2000) 23 777-811.
5. Koltzenburg M., Scadding J. Neuropathic pain. Curr. Opin. Neurol. (2001) 14 641-647.
6. Woolf C.J., Max M.B. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology (2001) 95 241-249.
7. Zeilhofer H.U. Loss of glycinergic and GABAergic inhibition in chronic pain - contributions of inflammation and microglia. Int. Immunopharmacol. (2008) 8 182-187.
8. Song G.H., Venkatraman V., Ho K.Y., Chee M.W., Yeoh K.G., Wilder-Smith C.H. Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls. Pain (2006) 126 79-90.
9. Merskey H., Watson G.D. The lateralisation of pain. Pain (1979) 7 271-280.
10. Jensen K.B., Kosek E., Petzke F. et al. Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain (2009) 144 95-100.
11. Treede R.D., Jensen T.S., Campbell J.N. et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology (2008) 70 1630-1635.
12. Green C.R., Anderson K.O., Baker T.A. et al. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med. (2003) 4 277-294.
13. Montagnini M.L., Zaleon C.R. Pharmacological management of cancer pain. J. Opioid Manag. (2009) 5 89-96.
14. Mercadante S., Gebbia V., David F. et al. Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients. J. Pain (2009) 10 594-600.
15. Edlund M.J., Steffick D., Hudson T., Harris K.M., Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain (2007) 129 355-362.
16. Pincus T., Vlaeyen J.W., Kendall N.A., Von Korff M.R., Kalauokalani D.A., Reis S. Cognitive-behavioral therapy and psychosocial factors in low back pain: directions for the future. Spine (2002) 27 E133-E138.
17. Blyth F.M., Macfarlane G.J., Nicholas M.K. The contribution of psychosocial factors to the development of chronic pain: the key to better outcomes for patients? Pain (2007) 129 8-11.
18. Andersson H.I., Ejlertsson G., Leden I., Rosenberg C. Chronic pain in a geographically defined general population: studies of differences in age, gender, social class, and pain localization. Clin. J. Pain (1993) 9 174-182.
19. Torrance N., Smith B.H., Bennett M.I., Lee A.J. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain (2006) 7 281-289.
20. Vlaeyen J.W., Linton S.J. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. Pain (2000) 85 317-332.
21. McBeth J., Macfarlane G.J., Hunt I.M., Silman A.J. Risk factors for persistent chronic widespread pain: a community-based study. Rheumatology (Oxford) (2001) 40 95-101.
22. Young Casey C., Greenberg M.A., Nicassio P.M., Harpin R.E., Hubbard D. Transition from acute to chronic pain and disability: a model including cognitive, affective, and trauma factors. Pain (2008) 134 69-79.
23. Peters M.L., Sommer M., de Rijke J.M. et al. Somatic and psychologic predictors of long-term unfavorable outcome after surgical intervention. Ann. Surg. (2007) 245 487-494.
24. Juhl G.I., Jensen T.S., Norholt S.E., Svensson P. Central sensitization phenomena after third molar surgery: a quantitative sensory testing study. Eur. J. Pain (2008) 12 116-127.
25. Breivik E.K., Bjornsson G.A., Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin. J. Pain (2000) 16 22-28.
26. Hicks C.L., von Baeyer C.L., Spafford P.A., van Korlaar I., Goodenough B. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain (2001) 93 173-183.
27. Melzack R.. Pain assesment in adult patients, 5th edn, Elsevier, London, UK, 2006.
28. Stubhaug A.. Clinical trials-acute and chronic pain, 2nd edn, Arnold, London, UK, 2008.
29. Dworkin R.H., Turk D.C., Farrar J.T. et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain (2005) 113 9-19.
30. Daut R.L., Cleeland C.S., Flanery R.C. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain (1983) 17 197-210.
31. LeBel A., Assesment of pain, in: Ballantyne J. (Eds), The Massachusetts General Hospital Handbook of Pain Managment. Lippincott Williams and Wilkins, Philadelphia, USA. 2006, 58-75.
32. Sokka T.. Assessment of pain in patients with reumatic diseases. Elsevier, London, UK, 2007.
33. Wittink H.. Pain managment: evidence, outcomes and quality of life. Elsevier, London, UK, 2008.
34. Wang X.. Pain managment: evidence outcomes and quality of life. Elsevier, London UK, 2008.
35. Chou R., Huffman L.H. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann. Intern. Med. (2007) 147 492-504.
36. Gatchel R.J., Peng Y.B., Peters M.L., Fuchs P.N., Turk D.C. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol. Bull. (2007) 133 581-624.
37. Molton I.R., Graham C., Stoelb B.L., Jensen M.P. Current psychological approaches to the management of chronic pain. Curr. Opin. Anaesthesiol. (2007) 20 485-489.
38. Portenoy R.K. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J. Pain Symptom Manage. (1996) 11 203-217.
39. Portenoy R.K., Bennett D.S., Rauck R. et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J. Pain (2006) 7 583-591.
40. Large R.G., Schug S.A. Opioids for chronic pain of non-malignant origin - caring or crippling. Health Care Anal. (1995) 3 5-11.
41. Angst M.S., Clark J.D. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology (2006) 104 570-587.
42. Katz N.P., Adams E.H., Benneyan J.C. et al. Foundations of opioid risk management. Clin. J. Pain (2007) 23 103-118.
43. Ballantyne J.C., Shin N.S. Efficacy of opioids for chronic pain: a review of the evidence. Clin. J. Pain (2008) 24 469-478.
44. Koch T., Hollt V. Role of receptor internalization in opioid tolerance and dependence. Pharmacol. Ther. (2008) 117 199-206.
45. Chang G., Chen L., Mao J. Opioid tolerance and hyperalgesia. Med. Clin. North Am. (2007) 91 199-211.
46. Gilson A.M., Ryan K.M., Joranson D.E., Dahl J.L. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J. Pain Symptom Manage. (2004) 28 176-188.
47. Caudill-Slosberg M.A., Schwartz L.M., Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain (2004) 109 514-519.
48. Kalso E., Edwards J.E., Moore R.A., McQuay H.J. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain (2004) 112 372-380.
49. Furlan A.D., Sandoval J.A., Mailis-Gagnon A., Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ (2006) 174 1589-1594.
50. Kalso E., Allan L., Dellemijn P.L. et al. Recommendations for using opioids in chronic non-cancer pain. Eur. J. Pain (2003) 7 381-386.
51. Graziotti P.J., Goucke C.R. The use of oral opioids in patients with chronic non-cancer pain. Management strategies. Med. J. Aust. (1997) 167 30-34.
52. Breivik H. Opioids in chronic non-cancer pain, indications and controversies. Eur. J. Pain (2005) 9 127-130.
53. Nedeljkovic S.S., Wasan A., Jamison R.N. Assessment of efficacy of long-term opioid therapy in pain patients with substance abuse potential. Clin. J. Pain (2002) 18 S39-S51.
54. Martin T.J., Ewan E. Chronic pain alters drug self-administration: implications for addiction and pain mechanisms. Exp. Clin. Psychopharmacol. (2008) 16 357-366.
55. Christie M.J. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br. J. Pharmacol. (2008) 154 384-396.
56. Bailey C.P., Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr. Opin. Pharmacol. (2005) 5 60-68.
57. Ueda H., Inoue M., Mizuno K. New approaches to study the development of morphine tolerance and dependence. Life Sci. (2003) 74 313-320.
58. Suzuki M., Tsueda K., Lansing P.S. et al. Small-dose ketamine enhances morphine-induced analgesia after outpatient surgery. Anesth. Analg. (1999) 89 98-103.
59. Foulkes T., Wood J.N. Pain genes. PLoS Genet (2008) 4 e1000086.
60. Priest B.T., Murphy B.A., Lindia J.A. et al. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behavior. Proc. Natl. Acad. Sci. U.S.A. (2005) 102 9382-9387.
61. Nassar M.A., Stirling L.C., Forlani G. et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc. Natl. Acad. Sci. U.S.A. (2004) 101 12706-12711.
62. Cox J.J., Reimann F., Nicholas A.K. et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature (2006) 444 894-898.
63. Zimmermann K., Leffler A., Babes A. et al. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. Nature (2007) 447 855-858.
64. Gold M.S., Levine J.D., Correa A.M. Modulation of TTX-R INa by PKC and PKA and their role in PGE2-induced sensitization of rat sensory neurons in vitro. J. Neurosci. (1998) 18 10345-10355.
65. Khasar S.G., Lin Y.H., Martin A. et al. A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron (1999) 24 253-260.
66. Tegeder I., Lotsch J.. Current evidence for a modulation of low back pain by human genetic variants. J. Cell Mol. Med. (2009) In press.
67. Kim J.G., Lim K.S., Ku S.Y., Kim S.H., Choi Y.M., Moon S.Y. Relations between interleukin-1, its receptor antagonist gene polymorphism, and bone mineral density in postmenopausal Korean women. J. Bone Miner. Metab. (2006) 24 53-57.
68. Solovieva S., Kouhia S., Leino-Arjas P. et al. Interleukin 1 polymorphisms and intervertebral disc degeneration. Epidemiology (2004) 15 626-633.
69. Solovieva S., Leino-Arjas P., Saarela J., Luoma K., Raininko R., Riihimaki H. Possible association of interleukin 1 gene locus polymorphisms with low back pain. Pain (2004) 109 8-19.
70. Noponen-Hietala N., Virtanen I., Karttunen R. et al. Genetic variations in IL6 associate with intervertebral disc disease characterized by sciatica. Pain (2005) 114 186-194.
71. Lee Y.S., Kim H., Wu T.X., Wang X.M., Dionne R.A. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin. Pharmacol. Ther. (2006) 79 407-418.
72. Malik-Hall M., Dina O.A., Levine J.D. Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. Eur. J. Neurosci. (2005) 21 3387-3394.
73. Obata K., Noguchi K. MAPK activation in nociceptive neurons and pain hypersensitivity. Life Sci. (2004) 74 2643-2653.
74. Beiche F., Scheuerer S., Brune K., Geisslinger G., Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett. (1996) 390 165-169.
75. Dubner R., Ruda M.A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. (1992) 15 96-103.
76. Ji R.R., Zhang X., Wiesenfeld-Hallin Z., Hokfelt T. Expression of neuropeptide Y and neuropeptide Y (Y1) receptor mRNA in rat spinal cord and dorsal root ganglia following peripheral tissue inflammation. J. Neurosci. (1994) 14 6423-6434.
77. Ino H., Ishizuka T., Chiba T., Tatibana M. Expression of CDK5 (PSSALRE kinase), a neural cdc2-related protein kinase, in the mature and developing mouse central and peripheral nervous systems. Brain Res. (1994) 661 196-206.
78. Terada M., Yasuda H., Kogawa S. et al. Expression and activity of cyclin-dependent kinase 5/p35 in adult rat peripheral nervous system. J. Neurochem. (1998) 71 2600-2606.
79. Dhavan R., Tsai L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. (2001) 2 749-759.
80. Woolf C.J., Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc. Natl. Acad. Sci. U.S.A. (1999) 96 7723-7730.
81. Mannion R.J., Costigan M., Decosterd I. et al. Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity. Proc. Natl. Acad. Sci. U.S.A. (1999) 96 9385-9390.
82. McCarson K.E., Krause J.E. NK-1 and NK-3 type tachykinin receptor mRNA expression in the rat spinal cord dorsal horn is increased during adjuvant or formalin-induced nociception. J. Neurosci. (1994) 14 712-720.
83. 2+/calmodulin-dependent protein kinase II and alpha-actinin-1 in a calcium-dependent manner. J. Neurosci. (2002) 22 7879-7891.
84. Chen J., Zhang Y., Kelz M.B. et al. Induction of cyclin-dependent kinase 5 in the hippocampus by chronic electroconvulsive seizures: role of [Delta]FosB. J. Neurosci. (2000) 20 8965-8971.
85. Pareek T.K., Kulkarni A.B. Cdk5: a new player in pain signaling. Cell Cycle (2006) 5 585-588.
86. Patapoutian A., Reichardt L.F. Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. (2001) 11 272-280.
87. Radeke M.J., Misko T.P., Hsu C., Herzenberg L.A., Shooter E.M. Gene transfer and molecular cloning of the rat nerve growth factor receptor. Nature (1987) 325 593-597.
88. Chao M.V. The membrane receptor for nerve growth factor. Curr. Top. Microbiol. Immunol. (1991) 165 39-53.
89. Ugolini G., Marinelli S., Covaceuszach S., Cattaneo A., Pavone F. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc. Natl. Acad. Sci. U.S.A. (2007) 104 2985-2990.
90. Ruiz G., Ceballos D., Banos J.E. Behavioral and histological effects of endoneurial administration of nerve growth factor: possible implications in neuropathic pain. Brain Res. (2004) 1011 1-6.
91. Ro L.S., Chen S.T., Tang L.M., Jacobs J.M. Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve. Pain (1999) 79 265-274.
92. Theodosiou M., Rush R.A., Zhou X.F., Hu D., Walker J.S., Tracey D.J. Hyperalgesia due to nerve damage: role of nerve growth factor. Pain (1999) 81 245-255.
93. Davis J.B., Gray J., Gunthorpe M.J. et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature (2000) 405 183-187.
94. Bhave G., Gereau R.Wt. Posttranslational mechanisms of peripheral sensitization. J. Neurobiol. (2004) 61 88-106.
95. Kwan K.Y., Allchorne A.J., Vollrath M.A. et al. TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction. Neuron (2006) 50 277-289.
96. Macpherson L.J., Xiao B., Kwan K.Y. et al. An ion channel essential for sensing chemical damage. J. Neurosci. (2007) 27 11412-11415.
97. Macpherson L.J., Dubin A.E., Evans M.J. et al. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature (2007) 445 541-545.
98. Bandell M., Story G.M., Hwang S.W. et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron (2004) 41 849-857.
99. Petrus M., Peier A.M., Bandell M. et al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol. Pain (2007) 3 40.
100. Ikeda K., Ide S., Han W., Hayashida M., Uhl G.R., Sora I. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol. Sci. (2005) 26 311-317.
101. Kasai S., Hayashida M., Sora I., Ikeda K. Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn Schmiedebergs Arch. Pharmacol. (2008) 377 269-281.
102. Kieffer B.L., Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog. Neurobiol. (2002) 66 285-306.
103. Sora I., Takahashi N., Funada M. et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. U.S.A. (1997) 94 1544-1549.
104. Monory K., Bourin M.C., Spetea M. et al. Specific activation of the mu opioid receptor (MOR) by endomorphin 1 and endomorphin 2. Eur. J. Neurosci. (2000) 12 577-584.
105. Fuchs P.N., Roza C., Sora I., Uhl G., Raja S.N. Characterization of mechanical withdrawal responses and effects of mu-, delta- and kappa-opioid agonists in normal and mu-opioid receptor knockout mice. Brain Res. (1999) 821 480-486.
106. Sora I., Li X.F., Funada M., Kinsey S., Uhl G.R. Visceral chemical nociception in mice lacking mu-opioid receptors: effects of morphine, SNC80 and U-50, 488. Eur. J. Pharmacol. (1999) 366 R3-R5.
107. Rubinstein M., Mogil J.S., Japon M., Chan E.C., Allen R.G., Low M.J. Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Proc. Natl. Acad. Sci. U.S.A. (1996) 93 3995-4000.
108. Konig M., Zimmer A.M., Steiner H. et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature (1996) 383 535-538.
109. Brady L.S., Herkenham M., Rothman R.B. et al. Region-specific up-regulation of opioid receptor binding in enkephalin knockout mice. Brain Res. Mol. Brain Res. (1999) 68 193-197.
110. Wang Z., Gardell L.R., Ossipov M.H. et al. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J. Neurosci. (2001) 21 1779-1786.
111. Bohn L.M., Gainetdinov R.R., Lin F.T., Lefkowitz R.J., Caron M.G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature (2000) 408 720-723.
112. Cen B., Xiong Y., Ma L., Pei G. Direct and differential interaction of beta-arrestins with the intracellular domains of different opioid receptors. Mol. Pharmacol. (2001) 59 758-764.
113. Cherny N., Ripamonti C., Pereira J. et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J. Clin. Oncol. (2001) 19 2542-2554.
114. Stein C. Peripheral mechanisms of opioid analgesia. Anesth. Analg. (1993) 76 82-191.
115. Ross J.R., Rutter D., Welsh K. et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. (2005) 5 324-336.
116. Lotsch J., Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain (2006) 121 1-5.
117. Oertel B.G., Schmidt R., Schneider A., Geisslinger G., Lotsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet. Genomics (2006) 16 625-636.
118. Lotsch J., Zimmermann M., Darimont J. et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology (2002) 97 814-819.
119. Chou W.Y., Yang L.C., Lu H.F. et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol. Scand. (2006) 50 787-792.
120. LaForge K.S., Yuferov V., Kreek M.J. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur. J. Pharmacol. (2000) 410 249-268.
121. Bart G., Heilig M., LaForge K.S. et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol. Psychiatry (2004) 9 547-549.
122. Sander T., Berlin W., Gscheidel N., Wendel B., Janz D., Hoehe M.R. Genetic variation of the human mu-opioid receptor and susceptibility to idiopathic absence epilepsy. Epilepsy Res. (2000) 39 57-61.
123. Klepstad P., Rakvag T.T., Kaasa S. et al. The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. (2004) 48 1232-1239.
124. Chou W.Y., Wang C.H., Liu P.H., Liu C.C., Tseng C.C., Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology (2006) 105 334-337.
125. Lotta T., Vidgren J., Tilgmann C. et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochem. (1995) 34 4202-4210.
126. Zubieta J.K., Heitzeg M.M., Smith Y.R. et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science (2003) 299 1240-1243.
127. Diatchenko L., Slade G.D., Nackley A.G. et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum. Mol. Genetics (2005) 14 135-143.
128. Nackley A.G., Tan K.S., Fecho K., Flood P., Diatchenko L., Maixner W. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain (2007) 128 199-208.
129. Reyes-Gibby C.C., Shete S., Rakvag T. et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain (2007) 130 25-30.
130. Mogil J.S., Ritchie J., Smith S.B. et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J. Med. Genet. (2005) 42 583-587.
131. Liem E.B., Joiner T.V., Tsueda K., Sessler D.I. Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficacy in redheads. Anesthesiology (2005) 102 509-514.
132. O'Farrell P.H. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. (1975) 250 4007-4021.
133. Niederberger E., Kuhlein H., Geisslinger G. Update on the pathobiology of neuropathic pain. Expert Rev. Proteomics (2008) 5 799-818.
134. Kang S.K., So H.H., Moon Y.S., Kim C.H. Proteomic analysis of injured spinal cord tissue proteins using 2-DE and MALDI-TOF MS. Proteomics (2006) 6 2797-2812.
135. Ding Q., Wu Z., Guo Y. et al. Proteome analysis of up-regulated proteins in the rat spinal cord induced by transection injury. Proteomics (2006) 6 505-518.
136. Bester H., Beggs S., Woolf C.J. Changes in tactile stimuli-induced behavior and c-Fos expression in the superficial dorsal horn and in parabrachial nuclei after sciatic nerve crush. J. Comp. Neurol. (2000) 428 45-61.
137. Rasko J.E., Klenova E.M., Leon J. et al. Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF. Cancer Res. (2001) 61 6002-6007.
138. Perlson E., Hanz S., Ben-Yaakov K., Segal-Ruder Y., Seger R., Fainzilber M. Vimentin-dependent spatial translocation of an activated MAP kinase in injured nerve. Neuron (2005) 45 715-726.
139. Kretz A., Schmeer C., Tausch S., Isenmann S. Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiol. Dis. (2006) 21 421-430.
140. Pesheva P., Kuklinski S., Schmitz B., Probstmeier R. Galectin-3 promotes neural cell adhesion and neurite growth. J. Neurosci. Res. (1998) 54 639-654.
141. Lee S.C., Yoon T.G., Yoo Y.I. et al. Analysis of spinal cord proteome in the rats with mechanical allodynia after the spinal nerve injury. Biotechnol. Lett. (2003) 25 2071-2078.
142. Sullivan P.G., Geiger J.D., Mattson M.P., Scheff S.W. Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol. (2000) 48 723-729.
143. Komori N., Takemori N., Kim H.K. et al. Proteomics study of neuropathic and nonneuropathic dorsal root ganglia: altered protein regulation following segmental spinal nerve ligation injury. Physiol. Genomics (2007) 29 215-230.
144. Jimenez C.R., Stam F.J., Li K.W. et al. Proteomics of the injured rat sciatic nerve reveals protein expression dynamics during regeneration. Mol. Cell Proteomics (2005) 4 120-132.
145. Tanaka S., Uehara T., Nomura Y. Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death. J. Biol. Chem. (2000) 275 10388-10393.
146. Katano T., Mabuchi T., Okuda-Ashitaka E., Inagaki N., Kinumi T., Ito S. Proteomic identification of a novel isoform of collapsin response mediator protein-2 in spinal nerves peripheral to dorsal root ganglia. Proteomics (2006) 6 6085-6094.
147. Arimura N., Menager C., Fukata Y., Kaibuchi K. Role of CRMP-2 in neuronal polarity. J. Neurobiol. (2004) 58 34-47.
148. Kunz S., Tegeder I., Coste O. et al. Comparative proteomic analysis of the rat spinal cord in inflammatory and neuropathic pain models. Neurosci. Lett. (2005) 381 289-293.
149. Hasue M. Pain and the nerve root. An interdisciplinary approach. Spine (1993) 18 2053-2058.
150. Zhang Y., Wang Y.H., Zhang X.H. et al. Proteomic analysis of differential proteins related to the neuropathic pain and neuroprotection in the dorsal root ganglion following its chronic compression in rats. Experimental brain research. Experimentelle Hirnforschung (2008) 189 199-209.
151. Donier E., Rugiero F., Okuse K., Wood J.N. Annexin II light chain p11 promotes functional expression of acid-sensing ion channel ASIC1a. J. Biol. Chem. (2005) 280 38666-38672.
152. Voilley N. Acid-sensing ion channels (ASICs): new targets for the analgesic effects of non-steroid anti-inflammatory drugs (NSAIDs). Curr. Drug Targets (2004) 3 71-79.
153. Numazaki M., Tominaga T., Toyooka H., Tominaga M. Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. J. Biol. Chem. (2002) 277 13375-13378.
154. Sweitzer S.M., Wong S.M., Peters M.C., Mochly-Rosen D., Yeomans D.C., Kendig J.J. Protein kinase C epsilon and gamma: involvement in formalin-induced nociception in neonatal rats. J. Pharmacol. Exp. Ther. (2004) 309 616-625.
155. Joseph E.K., Levine J.D. Sexual dimorphism in the contribution of protein kinase C isoforms to nociception in the streptozotocin diabetic rat. Neuroscience (2003) 120 907-913.
156. Joseph E.K., Levine J.D. Sexual dimorphism for protein kinase c epsilon signaling in a rat model of vincristine-induced painful peripheral neuropathy. Neuroscience (2003) 119 831-838.
157. Aley K.O., Messing R.O., Mochly-Rosen D., Levine J.D. Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C. J. Neurosci. (2000) 20 4680-4685.
158. Parada C.A., Yeh J.J., Reichling D.B., Levine J.D. Transient attenuation of protein kinase Cepsilon can terminate a chronic hyperalgesic state in the rat. Neuroscience (2003) 120 219-226.
159. Amadesi S., Cottrell G.S., Divino L. et al. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice. J. Physiol. (2006) 575 555-571.
160. Mazzola J.L., Sirover M.A. Subcellular localization of human glyceraldehyde-3-phosphate dehydrogenase is independent of its glycolytic function. Biochim. Biophys. Acta (2003) 1622 50-56.
161. Mayer D.J., Mao J., Holt J., Price D.D. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc. Natl. Acad. Sci. U.S.A. (1999) 96 7731-7736.
162. Li K.W., Jimenez C.R., van der Schors R.C., Hornshaw M.P., Schoffelmeer A.N., Smit A.B. Intermittent administration of morphine alters protein expression in rat nucleus accumbens. Proteomics (2006) 6 2003-2008.
163. Shui H.A., Ho S.T., Wang J.J. et al. Proteomic analysis of spinal protein expression in rats exposed to repeated intrathecal morphine injection. Proteomics (2007) 7 796-803.
164. Adam F., Bonnet F., Le Bars D. Tolerance to morphine analgesia: evidence for stimulus intensity as a key factor and complete reversal by a glycine site-specific NMDA antagonist. Neuropharmacology (2006) 51 191-202.
165. Tao Y.X., Raja S.N. Are synaptic MAGUK proteins involved in chronic pain? Trends Pharmacol. Sci. (2004) 25 397-400.
166. Tao Y.X., Johns R.A. PDZ domains at excitatory synapses: potential molecular targets for persistent pain treatment. Curr. Neuropharmacol. (2006) 4 217-223.
167. Walwyn W.M., Wei W., Xie C.W. et al. Mu opioid receptor-effector coupling and trafficking in dorsal root ganglia neurons. Neuroscience (2006) 142 493-503.
168. Payabvash S., Beheshtian A., Salmasi A.H. et al. Chronic morphine treatment induces oxidant and apoptotic damage in the mice liver. Life Sci. (2006) 79 972-980.
169. Guzman D.C., Vazquez I.E., Brizuela N.O. et al. Assessment of oxidative damage induced by acute doses of morphine sulfate in postnatal and adult rat brain. Neurochem. Res. (2006) 31 549-554.
170. Shadel G.S. Mitochondrial DNA, aconitase 'wraps' it up. Trends Biochem. Sci. (2005) 30 294-296.
171. Dastoor Z., Dreyer J. Nuclear translocation and aggregate formation of heat shock cognate protein 70 (Hsc70) in oxidative stress and apoptosis. J. Cell Sci. (2000) 113 2845-2854.
172. Nandi D.L., Horowitz P.M., Westley J. Rhodanese as a thioredoxin oxidase. Int. J. Biochem. Cell Biol. (2000) 32 465-473.